Insulet price target raised to $355 from $320 at Canaccord

Canaccord analyst Kyle Rose raised the firm’s price target on Insulet to $355 from $320 and keeps a Buy rating on the shares. The analyst said the target increase is to reflect our updated estimates as well as comparative valuation.